[CAS NO. 1262618-39-2] GS967
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1262618-39-2]
Store
Catalog
SLK-S5274
Brand
Selleck
CAS
1262618-39-2
DESCRIPTION [1262618-39-2]
Overview
| MDL | MFCD28385879 |
|---|---|
| Molecular Weight | 347.22 |
| Molecular Formula | C14H7F6N3O |
| SMILES | FC(C1=NN=C2C=CC(C3=CC=C(OC(F)(F)F)C=C3)=CN21)(F)F |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8800 mL | 14.4001 mL | 28.8002 mL |
| 5 mM | 0.5760 mL | 2.8800 mL | 5.7600 mL |
| 10 mM | 0.2880 mL | 1.4400 mL | 2.8800 mL |
| 50 mM | 0.0576 mL | 0.2880 mL | 0.5760 mL |
Description
GS967 (GS458967) is a potent and selective inhibitor of late I with anti-arrhythmic actions.
Targets
| late INa [1] |
| 0.13 μM |
In vitro
GS967 (3 μM) has no significant effect on L- or T-type calcium channel currents or Na+-Ca2+ exchanger current (INCX), and 1 μM GS967 has minimal or no effect on the ATP-inhibited K+ current or on human cardiac ion channels expressed in human embryonic kidney 293 or Chinese hamster ovary cells. GS967 is a novel sodium channel modulatorspecifically developed to inhibit persistent sodium current, with a 42-fold preference for persistent as opposed to peakcurrent inhibition.
In vivo
GS967 protects against seizures and prematurelethality in vivo. Chronic GS967 does not cause overt behavioraltoxicity or sedation in wild-type mice at theeffective anticonvulsant dose. GS967 suppresses arrhythmogenicity evoked by ischemia, hypokalemia, and catecholamines in canine and porcine models.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.